Complex Case Study: Type 2 Diabetes with Fatty Liver and Dyslipidaemia

Type 2 diabetes, fatty liver disease and dyslipidaemia commonly occur together, driven by shared mechanisms of insulin resistance and visceral and liver fat. Managing them together is more effective than treating each separately, but requires careful coordination of nutrition, activity, medicines and monitoring. This case, an illustrative composite, is organised as a problem list to show how each issue was handled within one integrated plan.

Presentation

A 56 year old office administrator was diagnosed with type 2 diabetes 4 years ago and takes metformin. Her HbA1c has risen to 64 mmol/mol. Her ALT is raised, and ultrasound shows fatty liver. Her LDL cholesterol is 3.8 mmol/L, triglycerides 3.1 mmol/L, HDL 0.9 mmol/L. Her blood pressure is 142/88. She has declined a statin previously because a friend had muscle pain on one. She takes a milk thistle supplement for her liver and berberine, which she read might replace diabetes medicines. She weighs 88 kg with a waist of 104 cm, sleeps poorly and walks little since knee pain began. She drinks wine at weekends. Her goal: “I want to stop getting worse, and I don’t want more tablets.”

Problem list

Problem 1: diabetes

Assessment: HbA1c 64 mmol/mol on metformin alone; kidney function normal; urine albumin to creatinine ratio mildly raised. Her diet is high in refined carbohydrate, with large portions of bread and pasta and fruit juice daily.

Plan: a structured nutrition plan focused on carbohydrate quality and quantity, protein at each meal, removal of fruit juice and vegetables first at meals. Her doctor reviews options for additional glucose lowering treatment, discussing medicines with benefits for weight, liver, heart and kidney. After discussion, she agrees to start one such medicine, given her albuminuria and cardiovascular risk. Decision owner: prescriber and patient.

Problem 2: fatty liver disease

Assessment: FIB 4 score in the indeterminate range, so elastography is arranged, showing moderate fibrosis. Hepatitis serology, iron studies and autoantibodies are negative.

Plan: weight loss of at least 7 to 10 percent, which is associated with improvement in liver fat and fibrosis; alcohol reduction; hepatology follow up given fibrosis. Milk thistle is discussed: evidence for benefit in fatty liver is limited, and she decides to stop it to reduce cost. Coffee, which she enjoys, is associated with lower liver disease risk in observational studies and can continue.

Problem 3: lipids and statin hesitancy

Assessment: her 10 year cardiovascular risk is high given diabetes, albuminuria, lipids and blood pressure. ApoB is raised. Lipoprotein(a) is normal.

Plan: the practitioner explores her concerns about statins without judgement. She is worried about muscle pain. The practitioner explains that in blinded trials, including an N of 1 trial, most muscle symptoms occurred similarly with placebo, that true statin muscle side effects are uncommon and reversible, and that statins are safe in fatty liver disease. Her absolute risk and likely benefit are presented using natural frequencies. She agrees to discuss a statin with her doctor, who starts one at a moderate dose. Decision owner: prescriber and patient.

Problem 4: blood pressure

Plan: home blood pressure monitoring; sodium reduction, particularly from bread and processed foods; weight loss; alcohol reduction; sleep assessment. Her doctor will review medication if home readings remain raised after 3 months.

Problem 5: supplements

Berberine can lower glucose and has some trial evidence, but combining it with metformin and a new glucose lowering medicine adds complexity, gastrointestinal side effects and interaction uncertainty, and it is not a replacement for prescribed treatment. After discussion, she stops it while her treatment is established, with the option to discuss it later with her doctor.

Problem 6: knee pain and activity

A physiotherapist assesses her knee osteoarthritis and prescribes strengthening exercises and a graded walking programme, with cycling as an alternative. Weight loss is expected to reduce knee load and pain.

Problem 7: sleep

She snores and wakes unrefreshed. A sleep study shows mild obstructive sleep apnoea. Treatment options are discussed; with weight loss and positional measures, her symptoms improve, and the sleep service plans reassessment.

Problem 8: alcohol

She drinks around 14 units at weekends. Given her liver fibrosis, she agrees to limit alcohol substantially and to have alcohol free weeks.

Follow up and outcomes

At 12 months, her blood pressure did not require additional medicine, and she walks daily with less knee pain. She takes more tablets than she wanted initially, but her health has improved on every measure, and she understands why each is there.

Reasoning notes

• Shared mechanisms, shared plan: weight loss, diet, activity, sleep and alcohol reduction improved every problem.
• Staging the liver changed management; FIB 4 alone was indeterminate.
• Respecting hesitancy while presenting evidence clearly allowed an informed decision about the statin.
• Supplements were reviewed, not simply accepted or dismissed.
• Medicines were not the enemy: her goal of fewer tablets was acknowledged, but medicines with benefits for heart, kidney and liver were part of good care.

One plan, many problems

This case shows how integrated care addresses clustered metabolic conditions: a clear problem list, shared mediators addressed first, prescriber decisions coordinated, evidence explained honestly and outcomes tracked across every problem.